Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study on the effectiveness of stenting for obstructive colorectal cancer at Niigata City Hospital

ABSTRACT: Primary outcome(s): Postoperative recurrence rate through 8 years after introduction of colorectal stent at Niigata City General Hospital.

DISEASE(S): Obstructive Colorectal Cancer

PROVIDER: 2655505 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Massachusetts General Hospital Atrial Fibrillation Study

Project description:Massachusetts General Hospital Atrial Fibrillation Study

| PRJNA297616 | ENA

Massachusetts General Hospital/Eisai NIMH Genetics Initiative Alzheimer's GWAS

Project description:Massachusetts General Hospital/Eisai NIMH Genetics Initiative Alzheimer's GWAS

| PRJNA156673 | ENA

Hospital Outbreak

Project description:Hospital Outbreak

| PRJNA187076 | ENA

Hospital Microbiome

Project description:Hospital Microbiome

| PRJEB31632 | ENA

Prolonged intra-neutrophil survival as an adaptive strategy of Staphylococcus aureus USA300 to the hospital environment

Project description:Methicillin-resistant Staphylococcus aureus (MRSA) is the causative agent of serious hospital- and community-associated infections. Due to the global rise in community-associated MRSA, the respective lineages are increasingly introduced into hospitals. This raises the question whether and, if so, how they adapt to this new environment. The present study was aimed at investigating how MRSA isolates of the USA300 lineage, infamous for causing infections in the general population, have adapted to the hospital environment. To this end, a collection of community- and hospital-associated USA300 isolates was compared by RNA-sequencing. Here we report that merely 460 genes were differentially expressed between these two epidemiologically distinct groups, including genes for virulence factors, oxidative stress responses and the purine, pyrimidine and fatty acid biosynthetic pathways. Differentially regulated virulence factors included leukotoxins and phenol-soluble modulins, implicated in staphylococcal escape from immune cells. We therefore investigated the ability of the studied isolates to survive internalization by human neutrophils. This showed that the community-associated isolates have the highest neutrophil-killing activity, while the hospital-associated isolates are better adapted to intra-neutrophil survival. Importantly, the latter trait protects internalized staphylococci against a challenge with antibiotics. We therefore conclude that prolonged intra-neutrophil survival serves as a relatively simple early adaptation of S. aureus USA300 to the hospital environment where antibiotic pressure is high.

2016-11-02 | GSE89394 | GEO

hospital wastewater

Project description:hospital wastewater Metagenome

| PRJNA989503 | ENA

hospital metagenome

Project description:hospital metagenome Genome sequencing

| PRJNA669480 | ENA

hospital metagenome

Project description:hospital metagenome Metagenomic assembly

| PRJNA668657 | ENA

Hospital Wastewater

Project description:Hospital Wastewater Metagenomic assembly

| PRJNA1056250 | ENA

Trial of colonic stenting for large bowel obstruction

Project description:Interventions: This study will compare the outcomes of colorectal surgery (bowel resection and possible stoma formation) versus colonic stent insertion using Ultraflex or Wallfex Precision Colonic Stent manufactured by Boston Scientific (TGA approved in Australia) to determine optimal management of non-curable colorectal cancer. Comparisons will be made between quality of life, length of stay, complications and cost to identify which group has the optimal outcome. The study will be conducted over 3 years. Primary outcome(s): To compare quality of life between surgical intervention and colonic stent insertion in the first 12 months following the procedure.[Daily until discharge from hospital, then at 1, 2, and 4 weeks and 3, 6 and 12 months] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Factorial;Type of endpoint: Efficacy

| 2452794 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data